Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. - Wikidata - wikimedia - TriplyDB

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

http://www.wikidata.org/entity/Q33943429

about

Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010 Inflammation, coagulation and cardiovascular disease in HIV-infected individuals Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients Challenges in initiating antiretroviral therapy in 2010.The Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS.Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections.Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study.The effect of alcohol use on IL-6 responses across different racial/ethnic groups.Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.Residual immune dysregulation syndrome in treated HIV infection.Immunity to HIV in Early Life Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters.Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals.Oxidative stress markers are increased since early stages of infection in syphilitic patients.Chronic HIV disease and activation of the coagulation system T cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis Biomarkers of immune dysfunction in HIV.Decreased IL-7 responsiveness is related to oxidative stress in HIV disease.Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial Plasma levels of soluble CD14 independently predict mortality in HIV infection.Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial Decreased chronic morbidity but elevated HIV associated cytokine levels in HIV-infected older adults receiving HIV treatment: benefit of enhanced access to care?An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses Dysbiotic bacteria translocate in progressive SIV infection.Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial.Microbial translocation and microbiome dysbiosis in HIV-associated immune activation Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.

P2860

Q26741384-6E8D6F9F-4F4D-4B45-8981-AB36A95957FA Q27690715-A1B63E40-9245-4A91-9EEB-149A2A570290 Q28483645-1ACD9E58-2DDD-4FBE-B863-D08EDB3D0848 Q28748971-617FCB6A-D517-45CA-901D-09FEF3A74EB4 Q30227046-6343DE7A-0972-43E1-B099-F693D33CC87E Q30381883-7F14A6B4-BE60-41BC-9EEE-2CE3DF5DB651 Q30558355-3CD34350-6085-4087-B55F-74FF4EE8E6F1 Q31127335-9373F8B7-3180-4F75-ACD5-A5BEF694B2E1 Q33406939-F946C748-81B2-4049-9565-2C50310801F4 Q33632786-69D5FA32-E76F-41D2-BB22-429CB5FFF4A5 Q33729360-23B1148A-79B7-44BE-845D-B076AAC056D5 Q33755753-CC117EEE-C33B-4ACC-B522-4A1A97FA04E0 Q33862741-FD8EEF07-20EB-4379-B4D4-DBB37988E2E6 Q33897898-9104E3B4-BBEF-4B5F-A3A8-9118FAE5E1C4 Q33926735-DCD11DEC-6B64-49C0-8467-DB0CEC81F62F Q34020121-D8D83253-27FF-4D38-9D8A-63C6143F568C Q34033051-90DA443D-18C2-4D33-A81C-D4F263D4C100 Q34091313-1CDCA445-8431-4F40-8F87-C9D17E7DEA84 Q34105477-364EBEC3-A606-47EB-9D05-2DBED8092767 Q34301916-C3077DE6-19F6-40D8-B0C0-8A7F10803173 Q34342368-8AFB34FA-872B-47FA-8691-1468F13852A5 Q34344703-804368BC-B7CE-434F-8671-E1A81DA243AD Q34351320-EB581FF9-154C-4C17-940A-DE4E4C0E4595 Q34387349-0C3AF98C-5EA3-4588-84FF-BAC1A8AA3095 Q34505245-4D412C86-E451-4EC0-971B-9F5AE53DB12E Q34546742-5F76BC63-29FE-4AB5-882F-C0F858C6145D Q34626044-BD7C6120-4651-47B2-88EF-1D97B3220283 Q34634839-EE080CD8-9D6D-4284-96CD-2BB1D4C72501 Q34662516-036D53ED-490F-45A2-B815-E5754F777228 Q34763977-53904C01-4558-4A8D-BD74-F80FE165CBF9 Q34764002-030FBA15-58AF-4132-AAE9-367204FDE356 Q34988273-805FD031-0FBC-4BF5-BDE0-B6032ADC2CB5 Q35006056-D26208E0-FBE1-4F77-B61B-A4F3EAE728B8 Q35021733-9CF918C5-31DD-48AD-8048-BCFCECFCD3A7 Q35077490-19DCB9B1-BAF5-4AA3-9EC6-D02EABFE24C6 Q35542433-23FE02A8-A23C-4DEF-B2B8-B1D65A4D831F Q35661912-1938892B-E54C-4AA0-A39D-15DA6975579D Q35777447-A73EF088-A4F6-4E01-9130-1132D6313436 Q35872112-EDFAF2F0-0350-48EA-B5E0-7A434D989E10 Q35873402-4DD4CA16-6B10-4773-8CB0-02A7C4CCF26D

P2860

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

http://www.wikidata.org/entity/Q33943429

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Activation and coagulation bio ...... n patients with HIV infection.

@ast

Activation and coagulation bio ...... n patients with HIV infection.

@en

type

label

Activation and coagulation bio ...... n patients with HIV infection.

@ast

Activation and coagulation bio ...... n patients with HIV infection.

@en

prefLabel

Activation and coagulation bio ...... n patients with HIV infection.

@ast

Activation and coagulation bio ...... n patients with HIV infection.

@en

P1433

Q33943429-D0EE4D8B-AE00-4669-A325-17958AC1AF2D

P1476

Q33943429-8F56FD27-00E7-40DC-BF18-0E48EF5D4963

P2093

Q33943429-15C7024D-DF7F-4C26-BCB6-4C6356D1FE17

Q33943429-1FEC0D8E-2817-4D7E-9596-2A7CA7621A74

Q33943429-3141B926-18E6-458D-8CD8-3E6DA7EC227F

Q33943429-7F75CB79-7BB2-4135-92ED-62CFEA66C75B

Q33943429-904045A4-AE6B-4FD7-AC41-9BDCCBEDD691

Q33943429-BACE9C42-0296-4EBF-823D-CD6AE13CB5D4

Q33943429-C013F115-A318-463D-90DF-70C4F65A50DD

Q33943429-EBD1AB62-4973-4DBF-88EA-3592CA17C89D

P2860

Q33943429-098BF144-34F5-4157-8540-700EA948334C

Q33943429-0DC6336B-D13F-4931-A86E-67F21A637605

Q33943429-0ED00D49-A651-4C84-9B55-F6D5D959D7E8

Q33943429-16A098AA-F786-4610-83DB-8BC98C958F43

Q33943429-17668983-608C-4838-BD5C-7452AB5F85DB

Q33943429-1ABB1876-3B1E-4FF1-BB1C-89E05F4C967A

Q33943429-23538183-FC4D-4D91-8E7E-16A104FE9600

Q33943429-2DB1D6E3-9053-4D08-8B34-CF1EA2A34748

Q33943429-3290EE76-0CDD-4134-9EBC-D7BDD95596CA

Q33943429-44AA18B2-F146-43C2-A2B4-43A165EBB701

P304

Q33943429-9FFBE55C-1BA7-4159-B162-77B4200A67D4

P31

Q33943429-9000DD05-A919-492D-B517-41E0E70DAAE1

P356

Q33943429-60E606B5-6D68-4B82-BC2A-654FF2DF26A8

P407

Q33943429-595D2A96-29B6-4209-A5A9-4CD36804E333

P433

Q33943429-21FB760C-F542-4450-930C-E3C7E7078A6D

P478

Q33943429-B370C911-E61E-4353-AC54-345280E34127

P50

Q33943429-0C973216-7FE6-44B6-BCAE-ECEC047D3B6E

Q33943429-127D4520-AE48-4AD1-A4E1-503C0DEE67EB

P577

Q33943429-7989356F-26DC-4E9F-85B4-236F0F8BEB0D

P5875

Q33943429-F3734BF5-B456-4E29-9862-45F81DE8B5B8

P698

Q33943429-CB83535C-3179-4DA5-84CC-E176A214D64B

P921

Q33943429-10ED3D77-E39B-4DD2-8AFF-46563BEEDFA8

P932

Q33943429-D6AB593A-A2C1-4F82-8AF7-CFC6C9DE86A7

P356

P1433

The Journal of Infectious Diseases

P1476

Activation and coagulation bio ...... n patients with HIV infection.

@en

P2093

Alison J Rodger

http://www.w3.org/2001/XMLSchema#string

Andrew N Phillips

http://www.w3.org/2001/XMLSchema#string

Athanassios Skoutelis

http://www.w3.org/2001/XMLSchema#string

Christoph Boesecke

http://www.w3.org/2001/XMLSchema#string

Daniela Gey

http://www.w3.org/2001/XMLSchema#string

INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group

http://www.w3.org/2001/XMLSchema#string

Lewis H Kuller

http://www.w3.org/2001/XMLSchema#string

Zoe Fox

http://www.w3.org/2001/XMLSchema#string

P2860

IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells

Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London

Serum amyloid A: an acute-phase protein involved in tumour pathogenesis

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

CD4+ count-guided interruption of antiretroviral treatment

Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer.

Determination of the underlying cause of death in three multicenter international HIV clinical trials.

Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages.

C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting.

P304

973-983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/605447

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

200

http://www.w3.org/2001/XMLSchema#string

P50

Matthew B. Goetz

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26740077

http://www.w3.org/2001/XMLSchema#string

P698

19678756

http://www.w3.org/2001/XMLSchema#string

P921

P932

2892757

http://www.w3.org/2001/XMLSchema#string